FDA approves Dupixent as add-on treatment for moderate-to-severe asthma – Sanofi + Regeneron
The FDA has approved Dupixent (dupilumab), from Sanofi + Regeneron, as an add-on maintenance treatment of patients aged 6 to 11 years with moderate-to-severe asthma characterized by an… read more.